🏛️ Verified NIH Record • Updated 2025-10-02
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (NCT06997081)
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: University of Miami
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (43 items) and avoid the listed exclusions (38 items).
Location: University of Miami — Miami, Florida
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Participants receiving \>1 cycle of prior treatment or concurrent systemic treatment for MM with the following exceptions:
- Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted
- Bone targeting agents are permitted
- Concurrent or prior treatment with corticosteroids for indications other than multiple myeloma is permitted
- Prior MM treatments, such as immunomodulatory drugs (IMIDs) or non-MM drugs in clinical trials for smoldering myeloma is permitted with a washout period of 2 weeks from last dose. Patients with Smoldering Multiple Myeloma (SMM) previously treated with carfilzomib are excluded.
- Patients with measurable disease who received up to one cycle of any therapy within 60 days with a washout period of 2 weeks from last dose (on a trial or outside a trial) are eligible (Note: Measurable disease is defined as one or more of the following: Serum monoclonal protein ≥ 1.0 g/dL, Urine monoclonal protein ≥ 200 mg/24 hour and/or involved serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal kappa/lambda ratio.)
- Known active central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement
- Major surgery within 14 days prior to enrollment
- Peripheral neuropathy (PN)/history of PN ≥ 3
- Patients who are receiving any other anti-myeloma investigational agents.
- Patients who receive a live attenuated vaccine within 4 weeks of scheduled study treatment administration.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- University of Miami — Miami, Florida
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.